|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2001-6-21
|
|
pubmed:abstractText |
Cross-linking of cell surface Fas molecules by Fas ligand or by agonistic anti-Fas Abs induces cell death by apoptosis. We found that a serine protease inhibitor, N-tosyl-L-lysine chloromethyl ketone (TLCK), dramatically enhances Fas-mediated apoptosis in the human T cell line Jurkat and in various B cell lines resistant to Fas-mediated apoptosis. The enhancing effect of TLCK is specific to Fas-induced cell death, with no effect seen on TNF-alpha or TNF-related apoptosis-inducing ligand-induced apoptosis. TLCK treatment had no effect on Fas expression levels on the cell surface, and neither promoted death-inducing signaling complex formation nor decreased expression levels of cellular inhibitors of apoptosis (FLICE inhibitory protein, X chromosome-linked inhibitor of apoptosis, and Bcl-2). Activation of the Fas-mediated apoptotic pathway by anti-Fas Ab is accompanied by aggregation of Fas molecules to form oligomers that are stable to boiling in SDS and beta-ME. Fas aggregation is often considered to be required for Fas-mediated apoptosis. However, sensitization of cells to Fas-mediated apoptosis by TLCK or other agents (cycloheximide, protein kinase C inhibitors) causes less Fas aggregation during the apoptotic process compared with that in nonsensitized cells. These results show that Fas aggregation and Fas-mediated apoptosis are not directly correlated and may even be inversely correlated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD95,
http://linkedlifedata.com/resource/pubmed/chemical/CASP8 and FADD-Like Apoptosis...,
http://linkedlifedata.com/resource/pubmed/chemical/CASP8 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CASP9 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CFLAR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 8,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 9,
http://linkedlifedata.com/resource/pubmed/chemical/Caspases,
http://linkedlifedata.com/resource/pubmed/chemical/Cycloheximide,
http://linkedlifedata.com/resource/pubmed/chemical/Intracellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Serine Proteinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Tosyllysine Chloromethyl Ketone,
http://linkedlifedata.com/resource/pubmed/chemical/X-Linked Inhibitor of Apoptosis...,
http://linkedlifedata.com/resource/pubmed/chemical/XIAP protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/anti-Fas monoclonal antibody,
http://linkedlifedata.com/resource/pubmed/chemical/immunosuppressive acidic protein
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
167
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
82-9
|
|
pubmed:dateRevised |
2008-5-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11418635-Adjuvants, Immunologic,
pubmed-meshheading:11418635-Antibodies, Monoclonal,
pubmed-meshheading:11418635-Antigens, CD95,
pubmed-meshheading:11418635-Apoptosis,
pubmed-meshheading:11418635-B-Lymphocytes,
pubmed-meshheading:11418635-CASP8 and FADD-Like Apoptosis Regulating Protein,
pubmed-meshheading:11418635-Carrier Proteins,
pubmed-meshheading:11418635-Caspase 8,
pubmed-meshheading:11418635-Caspase 9,
pubmed-meshheading:11418635-Caspases,
pubmed-meshheading:11418635-Cell Line, Transformed,
pubmed-meshheading:11418635-Cycloheximide,
pubmed-meshheading:11418635-Humans,
pubmed-meshheading:11418635-Intracellular Signaling Peptides and Proteins,
pubmed-meshheading:11418635-Jurkat Cells,
pubmed-meshheading:11418635-Lymphocyte Activation,
pubmed-meshheading:11418635-Neoplasm Proteins,
pubmed-meshheading:11418635-Protein Biosynthesis,
pubmed-meshheading:11418635-Proteins,
pubmed-meshheading:11418635-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:11418635-Serine Proteinase Inhibitors,
pubmed-meshheading:11418635-Signal Transduction,
pubmed-meshheading:11418635-T-Lymphocytes,
pubmed-meshheading:11418635-Tosyllysine Chloromethyl Ketone,
pubmed-meshheading:11418635-Tumor Cells, Cultured,
pubmed-meshheading:11418635-X-Linked Inhibitor of Apoptosis Protein
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Fas aggregation does not correlate with Fas-mediated apoptosis.
|
|
pubmed:affiliation |
Laboratory of Immunology, Division of Therapeutic Proteins, Food and Drug Administration, Center for Biologics and Evaluation and Research, Bethesda, MD 20892, USA. wicknery@ninds.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
